Synthesis, effect of substituents on the regiochemistry and equilibrium studies of tetrazolo[1,5-a]pyrimidine/2-azidopyrimidines

  1. 1 ,
  2. 2 ORCID Logo ,
  3. 2 ORCID Logo ,
  4. 2 ,
  5. 2 ,
  6. 2 ORCID Logo ,
  7. 2 ,
  8. 2 ORCID Logo ,
  9. 2 ORCID Logo ,
  10. 2 ORCID Logo and
  11. 2
1Laboratório de Química, Universidade Federal do Tocantins, Palmas, TO 77001-090, Brazil
2Núcleo de Química de Heterociclos (NUQUIMHE), Department of Chemistry, Federal University of Santa Maria (UFSM), 97105-900, Santa Maria, RS, Brazil
  1. Corresponding author email
Associate Editor: T. J. J. Müller
Beilstein J. Org. Chem. 2017, 13, 2396–2407.
Received 15 Jul 2017, Accepted 05 Oct 2017, Published 10 Nov 2017
Full Research Paper
cc by logo


An efficient synthesis methodology for a series of tetrazolo[1,5-a]pyrimidines substituted at the 5- and 7-positions from the cyclocondensation reaction [CCC + NCN] was developed. The NCN corresponds to 5-aminotetrazole and CCC to β-enaminone. Two distinct products were observed in accordance with the β-enaminone substituent. When observed in solution, the compounds can be divided into two groups: (a) precursor compounds with R = CF3 or CCl3, which leads to tetrazolo[1,5-a]pyrimidines in high regioselectivity with R at the 7-position of the heterocyclic ring; and (b) precursor compounds with R = aryl or methyl, which leads to a mixture of compounds, tetrazolo[1,5-a] pyrimidines (R in the 5-position of the ring) and 2-azidopyrimidines (R in the 4-position of the ring), which was attributed to an equilibrium of azide–tetrazole. In the solid state, all compounds were found as 2-azidopyrimidines. The regiochemistry of the reaction and the stability of the products are discussed on the basis of the data obtained by density functional theory (DFT) for energetic and molecular orbital (MO) calculations.


Tetrazolo[1,5-a]pyrimidines have attracted attention in the pharmaceutical field due to their significant potential to exhibit antitumor, antimicrobial, and antioxidant activities [1,2]. In addition to acting as a stimulant of the central nervous system [3], this class of substances plays an important role in drugs that are used to treat obesity, diabetes, hypertension, coronary heart disease, thyroid cancer, and hepatitis B virus [4-13].

Although many synthetic procedures used to obtain azolopyrimidines have been described in the literature [1,14-16], the synthesis of tetrazolo[1,5-a]pyrimidines, especially those that are formed from 5-aminotetrazole, such as 1,3-binucleophile synthons, have not been sufficiently discussed [17]. Today, several existing methods are known to have several disadvantages, including long reaction time, the use of harmful solvents, and multistep synthesis [18,19].

Moreover, researchers in the 1960s and 1970s reported the existence of an azide–tetrazole equilibrium in many heterocyclic systems, namely tetrazolopyridines, tetrazolopyridazines, tetrazolopyrimidines, tetrazoloazines, and tetrazolopurines. Both tetrazole and azide have different chemical properties. Among other factors, the nature of the substituents, solvent, temperature, and physical state of the compound (solid state or solution) are the properties that have the most influence on the azide–tetrazole equilibrium [20-28].

A comprehensive understanding of the azide–tetrazole equilibrium is of great interest from a pharmacological point of view. A broader control and modulation of the equilibrium can lead to a specific compound to prevent undesirable pharmacokinetics and biological properties arising from the differences in the chemical structure.

Our research group previously demonstrated an efficient and regioselective synthesis of pyrazolo[1,5-a]pyrimidines and aryl[heteroaryl]pyrazolo[1,5-a]pyrimidines in acetic acid under reflux. The regioselectivity was attributed to the high nucleophilicity of the amino group in 3-amino-5-methyl-1H-pyrazole and the high electrophilicity of the β-carbon atom of the enone, both soft sites of the starting materials [29]. In recent research, we developed an efficient method to obtain 1,2,4-triazolo[1,5-a]pyrimidines from the cyclocondensation reaction of 1,1,1-trifluoro-4-metoxy-3-alken-2-one or β-enaminones with 5-amino-1,2,4-triazole. The methodology using ultrasound irradiation promoted shorter reaction times, high regioselectivity, and excellent yields, when compared with conventional thermal heating [30]. Presently, we demonstrate an eco-friendly synthesis of 5- and 7-substituted tetrazolo[1,5-a]pyrimidine isomers, in good to excellent yields, using ionic liquids and water as solvents, and short reaction times. In addition, 5-substituted isomers have proved to be excellent models in carrying out a thorough investigation of the azide–tetrazole equilibrium mechanism by density functional theory (DFT) and various experimental methods (e.g., NMR, SCXRD, PXRD, FTIR).

Therefore, this study aims to (i) propose an efficient methodology for the synthesis of tetrazolo[1,5-a]pyrimidines substituted at the 5- and 7-positions of the heterocyclic ring; (ii) observe the regiochemistry of the cyclocondensation reaction and the effect of the substituent on the β-enaminone precursor and (iii) elucidate the azide–tetrazole equilibrium when the compound is in solid form or dissolved in distinct solvents. The tetrazolo[1,5-a]pyrimidine synthesis was conducted from a cyclocondensation reaction of the type [CCC + NCN], in which the CCC block is a series of β-dimethylamino vinyl ketones, and the NCN block is 5-aminotetrazole.

Results and Discussion

Synthesis of tetrazolo[1,5-a]pyrimidines

The β-dimethylamino vinyl ketones (β-enaminones) were synthesized using methodologies previously described by our research group [31]. In order to achieve better reaction conditions for the preparation of tetrazolo[1,5-a]pyrimidines, the reaction of β-enaminone 1a with 5-aminotetrazole (2) was carried out under several conditions using conventional solvents and ionic liquids (ILs) to provide 5-phenyltetrazolo[1,5-a]pyrimidine (3a).

Two conditions in which the product exceeded 80% yield were found: (i) toluene reflux in the presence of HCl for 16 h (entry 2, Table 1), and (ii) ionic liquid [HMIM][TsO] at 120 °C in the presence of HCl for 5 min or 2.5 h (entries 7 and 8, respectively, Table 1). Nevertheless, the use of the IL [HMIM][TsO] proved advantageous when compared to toluene due to the considerable difference in reaction time (IL (5 min) in comparison with toluene (16 h)). This can be attributed to the significant stabilization of charges in the activated complex of the reaction promoted by charged [HMIM][TsO]. Other advantages regarding special properties (such as high thermal stability and low volatility) of ILs can be considered. Reactions in [BMIM][BF4] and [HMIM][TsO] using p-toluenesulfonic acid (p-TsO) as a catalyst were unsuccessful and have been omitted from Table 1.

Table 1: Reaction conditions for the synthesis of compounds 3a/4a.

[Graphic 1]
entry solventa temp. (°C) time acidb yield (%)c
1 AcOH reflux 16 h 0
2 toluene reflux 16 h HCl 83
3 [BMIM][BF4] 120 6 h 0
4 [BMIM][BF4] 120 5 min HCl 0
5 [BMIM][BF4] 120 2.5 h HCl 54
6 [BMIM][BF4] 120 6 h HCl 60
7 [HMIM][TsO] 120 5 min HCl 82
8 [HMIM][TsO] 120 2.5 h HCl 80
9 [HMIM][TsO] 120 6 h HCl 63

aSolvent: 5 mL; IL: 1 mmol. b0.1% of catalyst. cIsolated product yield.

The best conditions that were found for 1a and 5-aminotetrazole (2) were used for the reaction of 2 with β-enaminones 1bi (Table 2). The products formed from the reaction of 1a–g with 5-aminotetrazole were detected as a tetrazolo[1,5-a]pyrimidine[Graphic 5]2-azidopyrimidine (3[Graphic 6]4) equilibrium in solution, which were identified by NMR. On the other hand, the reaction of 1h,i with 5-aminotetrazole (2) was highly regioselective and yielded tetrazolo[1,5-a]pyrimidines 5h,i, in which R = CF3 and CCl3 and presented exclusively R at the 7-position of the heterocyclic ring (Table 2). The tetrazolo[1,5-a]pyrimidine[Graphic 7]2-azidopyrimidine (3[Graphic 8]4) equilibrium will be discussed in detail later in this article. All products were formed in good to excellent yields (40–96%). To the best of our knowledge, all synthesized compounds, with the exception of 3a:4a, 3g:4g, and 5h [21,32], have not been previously described in the literature. Acid catalysts and conventional organic solvents were used for the cyclization of enaminones [33,34]. This method provided good yields and regioselectivity using a simple catalyst and an IL as the solvent. Notably, not only the reaction time was short, but the purification process is simple.

Table 2: Synthesis of compounds 3a–g, 4a–g and 5h,i.

[Graphic 2]
product R yielda (%) molar ratiob
[HMIM][TsO] toluene 3:4
3a:4a Ph 82 87 84:16
3b:4b 4-F-C6H4 83 85 79:21
3c:4c 4-Cl-C6H4 91 88 85:15
3d:4d 4-Br-C6H4 95 87 79:21
3e:4e 4-I-C6H4 86 96 89:11
3f:4f 4-CH3-C6H4 89 91 93:7
3g:4g 4-OCH3-C6H4 93 78 94:6
5h CF3 70 40 100c
5i CCl3 68 77 100c

aIsolated product yield. bThe 3:4 molar ratio was calculated based on the aromatic hydrogens in the 1H NMR spectrum using DMSO-d6 for products obtained in [HMIM][TsO]. Compounds 3a:4a, 3g:4g were already published [21] in a proportion of 59:41 and 57:43 in CDCl3, respectively. Compound 5h was previously observed as 1,7-isomer [32]. cWas only observed as a single product in CDCl3.

The regiochemistry of tetrazolo[1,5-a]pyrimidines

The regiochemistry of tetrazolo[1,5-a]pyrimidines can be verified by 1H NMR spectroscopy. The substituted tetrazolo[1,5-a]pyrimidines found in the literature [21,32] presented coupling constants of 3JH-H = 6.9–7.3 Hz for H6–H7, and 3JH-H = 4.2–4.8 Hz for H5–H6. The coupling constant for compound 3a is 3JH-H = 7.3 Hz, while compound 5h has a coupling constant of 3JH-H = 4.9 Hz, which characterizes the substitution at the 5-position and 7-position of the heterocyclic ring, respectively (Figure 1).


Figure 1: Hydrogen coupling constants (3JH-H) of (a) H6–H7 for 3a and (b) H5–H6 for 5h.

The formation of 7-trihalomethyl-substituted (R = CF3 and CCl3) tetrazolo[1,5-a]pyrimidine when β-enaminones were reacted with 5-aminotetrazole showed that the structure of the R group affects the regiochemistry of the products formed.

The β-enaminones 1ag (R = aryl) result predominantly in 5-aryl-substituted tetrazolo[1,5-a]pyrimidines 3ag. β-Enaminones 1h,i (R = CF3 and CCl3) result in a highly regioselective synthesis of tetrazolo[1,5-a]pyrimidines 3h,i with CX3 groups at the 7-position of the fused pyrimidine ring.

The well-defined regiochemistry of these reactions, according to the substituent, can be understood by determination of the LUMO coefficients of the carbonyl (C1) and the β-carbon (C3) of the β-enaminones. The LUMO coefficient values for neutral and conjugated acids of β-enaminones with R = phenyl (1a) and CF3 (1h) were determined using the Gaussian 09 software package [35] and calculated at B3LYP/cc-pVTZ level of theory (Figure 2).


Figure 2: LUMO coefficients for (a) β-enaminones 1a,h, and their (b) conjugated acids.

Under neutral conditions, the highest LUMO coefficient in the β-enaminones with R = phenyl and CF3 can be found at the β-carbon C3 (Figure 2a). Under acidic conditions, in which the reactions were performed, C1 is the carbon with the highest LUMO coefficient (0.235) when R = phenyl (Figure 2b). Consequently, the first nucleophilic attack from the amino group of 5-aminotetrazole occurs at C1, leading to the formation of the 5-aryl-substituted compound 3a. On the other hand, when R = CF3, the highest LUMO coefficient (0.262) is located at the C3 carbon of the β-enaminone (Figure 2b). Therefore, the initial nucleophilic attack leads to the formation of the 7-trifluoromethyl-substituted compound 5h. The first nucleophilic attack from the amino group of 5-aminotetrazole was evidenced by HOMO coefficient calculations (Table S3 in Supporting Information File 1). The highest HOMO coefficient for the NH2 group indicates the superior nucleophilicity of the NH2 group in the aminotetrazole molecule. A scheme that illustrates the first nucleophilic attack that leads to different isomers according to the β-enaminone substituent can be seen in Figure S1 in Supporting Information File 1.

The synthesis of tetrazolo[1,5-a]pyrimidines 3ag and 2-azidopyrimidines 4ag were confirmed from the 1H and 13C NMR spectra and mass spectrometry. Chemical shift assignments and coupling constants of pyrimidine ring hydrogens were compared with compounds 3a, 4a, 3g, 4g, and 5h described in the literature [21,32]. The HMQC and HMBC 1H–13C were carried out in order to confirm the signal attributions (see Figures S5 and S6 in Supporting Information File 1).

The 1H NMR spectra of 3ag:4ag show the aromatic protons H6 and H7 as doublets in the region between 8.11–8.24 ppm and 9.69–9.82 ppm, respectively, with 3JH-H = 7.3 Hz attributed to 5-aryl-substituted tetrazolo[1,5-a]pyrimidines. The 4a–g signals show the H5 and H6 aromatic hydrogens as doublets at 7.78–7.89 ppm and 8.67–8.79 ppm, respectively, where 3JH-H = 5.3 Hz characterizes the azide derivatives. The analysis of the 1H NMR data of compounds 5h,i shows the aromatic protons H5 and H6 as doublets in the region between 7.38–7.67 ppm and 8.80–8.85 ppm, respectively. The 3JH-H coupling constants of the aromatic H5 and H6 protons are around 4.8–5.2 Hz, which is a characteristic of the 7-substituted compound.

The 13C NMR spectra of 3ag:4ag show C6 from δ 109.7 to 110.9, C7 from δ 135.1 to 143.3, C3a from δ 154.7 to 155.3, and the carbon C5 from δ 163.4 to 165.0, respectively. The 13C NMR data for 4ag show C5 from δ 112.7 to 113.5, C6 from δ 135.5 to 160.9, C2 from δ 160.3 to 163.9, and C4 from δ 163.0 to 167.4, respectively. The analysis of the 13C NMR data of compounds 5h,i shows C6 from δ 111.3 to 112.3, C7 from δ 157.7 to 161.5, C3a from δ 161.5 to 162.3, and C5 from δ 163.2 to 168.0, respectively.

The equilibrium of tetrazolo[1,5-a]pyrimidines in solution

As previously mentioned, the products obtained from the reaction of 5-aminotetrazole with 1ag are observed as a mixture of compounds 3ag:4ag based on the 1H and 13C NMR spectra performed in DMSO-d6. These 1H and 13C NMR analyses of 3d:4d in DMSO-d6 showed a mixture of tetrazolo[1,5-a]pyrimidine 3d and 2-azidopyrimidine 4d, which suggested the existence of a tetrazolo[1,5-a]pyrimidine[Graphic 9]2-azidopyrimidine equilibrium (3d[Graphic 10]4d, Figure 3a,b).


Figure 3: (a) 1H and (b) 13C NMR spectra demonstrating the 3d[Graphic 9]4d equilibrium in DMSO-d6 at 25 °C.

In solution, the tetrazole–azido equilibrium is influenced by the polarity of the solvent. Upon increasing the solvent polarity, an increase in the amount of the tetrazole form in equilibrium is usually observed [28,36]. In general, the tetrazole form 3ag is predominant in the mixture at a proportion greater than 4:1 relative to the azide form 4ag. The molar ratio of 3ag:4ag, which was obtained from the 1H NMR using DMSO-d6 as a solvent, is presented in Table 2. Although the products 3ag:4ag have low solubility in CDCl3, it was possible to record the 1H NMR spectrum of the mixture 3d:4d in this solvent. From the 1H NMR, it was possible to determine that over 90% of the mixture is in the form of 2-azidopyrimidine 4d in CDCl3. This proves the effect of the solvent in the tetrazolo[1,5-a]pyrimidine[Graphic 11]2-azidopyrimidine equilibrium. The highly polar DMSO-d6 favors the ring closure to form tetrazolo[1,5-a]pyrimidines in larger quantities (3d:4d in a proportion of 80:20). On the other hand, the less polar solvent CDCl3 induces the formation of 2-azidopyrimidine 4d at a proportion of 10:90. Here, the ring is opened to form the azide group bonded in the pyrimidine ring. This result is in agreement with the literature data [20-22,24-27,32].

To corroborate with the data, the dipole moment (µ) of two forms (3a and 4a) were estimated using the Gaussian 09 software package [35]. The dipole moment found for 3a and 4a was 7.47 D and 3.83 D, respectively. These results reveal why the tetrazole form is favored in DMSO-d6 when compared to CDCl3, since the dipole moment of the DMSO-d6 is greater than the dipole moment of CDCl3, in addition to being able to stabilize the tetrazole form more effectively. Moreover, the results from quantum mechanical calculation confirmed that the tetrazole 3a form is 2.98 kcal mol−1 more stable in DMSO-d6 when compared to its stability in CDCl3. A study of the azide–tetrazole equilibrium in several furo[2,3-e][1,5-c]pyrimidines was also performed by Sirakanyan et al. [36]. They showed that upon increasing the solvent polarity of CCl4 (ε 2.3) to DMSO-d6 (ε 46.7), the amount of the tetrazolo form increases (from 6% to 93%) in the equilibrium. These data corroborate the results herein regarding the influence of the solvent. It is important to note that the equilibrium is only established when the tetrazolo[1,5-a]pyrimidine is 5-substituted. 7-substituted compounds 5h,i were obtained as single products.

Recently, our research group demonstrated a highly regioselective synthesis of a series of trifluoromethylated tetrazolo[1,5-a]pyrimidines with potent antimicrobial activity [37]. The reaction between several β-alkoxyvinyl trifluoromethyl ketones [CF3C(O)CH=C(R)OCH3] (in which R = Ph, 4-F–C6H4, 4-Cl–C6H4, 4-Br–C6H4, 4-I–C6H4, 4-CH3–C6H4, 4-OCH3–C6H4, thien-2-yl, 4-Ph–C6H4, CH3) and 5-aminotetrazole, by using conventional heating in an oil bath or microwave irradiation, was performed in IL. Here, only the 5-trifluoromethyl-substituted tetrazolo[1,5-a]pyrimidines 6ag were obtained in all cases. Some important structures for the current study are depicted in Table 3. The results were correlated with LUMO coefficient data of β-alkoxyvinyl trifluoromethyl ketones, in which the first nucleophilic attack of the 5-aminotetrazole amino group occurs in the C4 [37]. The absence of the tetrazolo[1,5-a]pyrimidine[Graphic 11]2-azidopyrimidine equilibrium in solution in CDCl3 or DMSO-d6, in this case, can be attributed to the presence of the CF3 group at the 7-position of the ring. The energy data from DFT calculations for 6a in CDCl3 (8.92 kcal mol−1) and DMSO-d6 (7.65 kcal mol−1) indicate that the tetrazole form is more stable than the azide in both solvents evaluated. Unexpectedly, the tetrazole form is slightly more stable in CDCl3 when CX3 is bonded at the 7-position of the ring.

Table 3: Structures of trihalomethylated tetrazolo[1,5-a]pyrimidines.

[Graphic 3]
compound R X
6a Ph F
6b 4-Br–C6H4 F
6c 4-OCH3–C6H4 F
6d 4-F–C6H4 F
6e 4-Cl–C6H4 F
6f 4-CH3–C6H4 F
6g CH3 F
6ha Ph Cl
6ia CH3 Cl

aFor synthesis, see Experimental section.

Moreover, the 15N NMR analysis was carried out for compounds 6a and 6g. The spectra of the phenyl-substituted compound 6a, in CDCl3, showed a signal at δ 114.8, which is consistent with sp3 nitrogen. This signal was attributed to N1. The N5, N4, N2, and N3 atoms appear at δ 237.1, 241.3, 252.4, and 265.7, respectively. The data obtained from the 15N NMR spectrum confirms the structure of trifluoromethylated tetrazolo[1,5-a]pyrimidines in solution (See Figures S8 and S9 in Supporting Information File 1) [38-40].

Conversely, in an attempt to extend the studies in this area and to confirm the possibility of the tetrazolo[1,5-a]pyrimidines[Graphic 12]2-azidopyrimidine equilibrium for trifluoromethylated tetrazolo[1,5-a]pyrimidines in solution, three reactions were planned between phenylacetylene and compounds 6ac.

The 1,2,3-triazole synthesis from the 1,3-dipolar cycloaddition reaction between 6ac and terminal alkynes catalyzed by copper salts (CuAAC) [41-43] confirms that the reaction passes through an azide intermediate. In addition to mild reaction conditions and short reaction times, the advantage of CuAAC is the formation of 1,2,3-triazoles-1,4-disubstituted in a highly regioselective manner [41]. Recently, Cornec et al. [44] synthesized 4,6-dimethyl-2-(4-aryl-1H-1,2,3-triazol-1-yl)pyrimidines from azides using copper salts. The reaction involved the in situ reduction of the Cu(II) salt by sodium ascorbate.

The reactions in this study were performed from the 1,3-dipoloar cycloaddition reaction catalyzed by Cu(I) [44] and the 1,4-disubstituted 1,2,3-triazoles 8a–c were acquired in excellent yields (Table 4). Although only compounds 6a–c were observed in solution, the different conditions at which the compounds were introduced can induce the establishment of an equilibrium and the presence of an azide in solution. This data indicates that the equilibrium between these two are complex and depend on conditions beyond the nature of the substituent of the tetrazolo[1,5-a]pyrimidines and/or the solvent used to dissolve the compounds.

Table 4: Reaction conditionsa and yieldsb of 8a–c.

[Graphic 4]
product R yield (%)b
8a H 91
8b Br 94
8c OCH3 93

aReaction conditions: phenylacetylene, CuSO4·2H2O (10 mol %), sodium ascorbate (20%), tert-BuOH/H2O (1:1), 60 °C, 24 h. bIsolated product yield.

The equilibrium of tetrazolo[1,5-a]pyrimidine and 2-azidopyrimidine in the solid state

Furthermore, as observed in the literature, in the solid state or in DMSO-d6, the tetrazolo[1,5-a]pyrimidines are favored or predominant in the tetrazolo[1,5-a]pyrimidine[Graphic 12]2-azidopyrimidine equilibrium [1,21-24,26,27]. Additionally, from quantum mechanical calculations, it was possible to note that compound 3a (tetrazole form) is 1.54 kcal mol−1 more stable than 4a (azide form) in the solid state.

To corroborate this result, compounds 6a,b,df (previously described in reference [37]) were evaluated from the solid state equilibrium point of view (Figure 4). To evaluate the predominant form in the solid state, compounds 6a,b,df were crystallized and single crystal X-ray diffraction (SCXRD) data were collected. In the solid state, the analysis revealed that the products 6a,b,df are, in fact, in the 2-azidopyrimidine form 7a,b,df. It is opposite the trend regarding compound 3a from DFT data. The ORTEP® plot of 7a is depicted in Figure 4. The ORTEP® plot of 7b and 7df can be observed in Figure S10 in Supporting Information File 1.


Figure 4: ORTEP® [45] plot of 7a with thermal ellipsoids drawn at 50% probability level.

Similar to our study, Sirakanyan et al. [46] presented the synthesis and structure of condensed triazolo- and tetrazolopyrimidines, wherein, in DMSO-d6, tetrazolo-azidopyrimidines were in equilibrium. However, the structure confirmed by X-ray crystallography was the tetrazole form, which is different from our results. This demonstrates how different factors, such as the nature of the substituents and influence of solvents, can change the tetrazole–azide equilibrium.

For this series, when the compounds crystallize (solid form), the equilibrium is shifted to the opened aromatic ring, resulting in a 2-azidopyrimidine compound. The structures of compounds 7a,b and 7f were also confirmed by IR spectroscopy in the solid state. The FTIR spectrum, recorded using a KBr pellet, exhibited a strong absorption band corresponding to the azido group [47] at 2140 cm−1 and 2160 cm−1, thus corroborating the SCXRD results (see Figures S11–S13 in Supporting Information File 1).

Despite the considerable amount of experimental data reported in the literature regarding the azido–tetrazole equilibrium, quantum mechanical studies in this context have yet to be thoroughly explored. This approach provides energy data about the stabilization of the different forms, solvent effects, and shows that the azide–tetrazole transformation is initiated by a p–π atomic orbital overlap rather than an electrostatic attraction process [48]. To detect which form is more stable in the solid state, quantum mechanical calculations were performed using the Gaussian 09 software package [35] and B3LYP/cc-pVTZ level of theory for 6a and 6g. The results suggest that the 2-azidopyrimidine derivatives 7ag are about 10 kcal mol−1 more stable than the tetrazolo[1,5-a]pyrimidine derivatives 6ag. Figure 5 shows the trifluoromethylated tetrazolo[1,5-a]pyrimidine structures favored in different conditions in equilibrium.


Figure 5: Tetrazolo[1,5-a]pyrimidine observed in solution (CDCl3 and DMSO-d6) and 2-azidopyrimidine observed in the solid state based on equilibrium.

To support this data, compound 6h,i (X = Cl) was synthesized using the methodology described in [37]. In a CDCl3 or DMSO-d6 solution, the compounds 6h,i were identified as tetrazolo[1,5-a]pyrimidines (1,5-isomer). Surprisingly, in the solid state (after the crystallization process), compounds 6i (or 7i – azide form) were not observed. In this case, the 7-substituted 5-(trichloromethyl)tetrazolo[1,5-a]pyrimidine was found, in which the CCl3 group is bonded at the 5-position of the heterocyclic ring, while CH3 is bound at the 7-position (8i, Figure 6). The observation was supported by DFT data, in which the tetrazole form was found to be 2.84 kcal mol−1 more stable than its azide form. This indicates that an unusual equilibrium is established for 6i (i.e., when R = CH3) in the crystallization process (Figure 7). Notwithstanding, 6h was found in the usual azide form in the solid state 7h (see Figure S10 in Supporting Information File 1).


Figure 6: ORTEP® [45] plot of 8i with thermal ellipsoids drawn at 50% probability level.


Figure 7: Representation of the possible equilibrium existing between 6i, 7i, and 8i.

Compound 8i can be formed when 6i passes through the azide intermediary 7i (open ring) due to the presence of the 6i:7i equilibrium. When the azide form 7i reacted to tetrazolo 8i, the nitrogen atom next to the methyl group participates in the ring closure. This equilibrium was not observed in the other compounds addressed in this work.

In general, tetrazolo[1,5-a]pyrimidines with 7-CF3 or 7-CCl3 substituents were observed in DMSO-d6 or CDCl3, while 2-azidopyrimidine was found in the solid state. As previously mentioned, the existence of the tetrazolo form in solution can be explained by the presence of electron-withdrawing groups (CX3) which stabilize this form. On the other hand, in solid state the azide form (more thermodynamically stable) predominates, except for 8i.

Abu-Eittah et al. [49] theoretically investigated the substituent effect of azidothiazoles in the azido–tetrazole equilibrium using the B3LYP/6-311G** level of theory. Their results showed that electron-withdrawing groups (–NO2, –CN) stabilize azide isomers while –NH2 and –OH groups shift the equilibrium to the tetrazole side. Furthermore, energy calculations demonstrated that tetrazole is less stable than the azide isomer by an amount of energy between 16.02 and 5.44 kcal mol−1. In this case, compounds with NO2 and NH2 substituent has the highest and lowest value, respectively. Coutinho et al. [20] found the same tendency while studying a series of substituents at the 5-position of tetrazolo[1,5-a]pyridines using ab initio calculations. Their findings indicated that electron-withdrawing groups stabilize the azide isomer while electron-donating groups stabilize the tetrazole ring. Additionally, it was observed that NO2 has the largest effect on the equilibrium, stabilizing the azide by 7.0 kcal mol−1 in comparison with the tetrazole. Based on these results, our data are considered to be in accordance with the literature. Therefore, the authors suggest that the CX3 electron-withdrawing groups at the 7-position also present important effects to obtain azide isomers in the solid state (7a,b,d–f) since, with the exception of R = CH3 at the 5-position (8i), all the substituents were supplied in the azide form in the solid state.


A highly regioselective synthesis of triazolo[1,5-a]pyrimidines according to the substituent of the β-enaminone 1 was reported. All products were obtained in good to excellent yields (40–96%) and 13 compounds were described for the first time. It was shown that aryl (electron-donating) and CX3 (electron-withdrawing) groups in precursor 1 lead to 5-substituted and 7-substituted triazolo[1,5-a]pyrimidine compounds, respectively. The results indicate that the reaction regiochemistry is governed by the group bound to the carbonyl of the β-enaminones. In addition, the tetrazole–azide equilibrium was only detected in solution (DMSO-d6) for the 1,5-isomers 3ag:4ag. In this case, the predominant form was tetrazole. When 3d:4d was evaluated in CDCl3, a proportion of 10:90 was observed, which corroborates with predominant forms already described in the literature for triazolo[1,5-a]pyrimidines in both solvents. From the DFT calculations, it was possible to predict that the tetrazole form can be expected in the solid state.

Based on these data, some important insights about the equilibrium in the solid state for 7-trihalomethyl-substituted tetrazolo[1,5-a]pyrimidines were also reported. Unexpectedly, these products were observed predominantly in the tetrazole form 6ah in solution (CDCl3 and DMSO-d6), while azide species 7ah were observed in the solid state. Notwithstanding, although only the tetrazoles were observed for compounds 6ac in solution, the conditions at which the compounds were introduced can induce the equilibrium to favor the presence of the azides (e.g., reaction conditions to achieve 8ac). In the solid state, the DFT results revealed that the 2-azidopyrimidine derivatives 7ah are approximately 10 kcal mol−1 more stable than tetrazolo[1,5-a]pyrimidine derivatives 6ah, which is consistent with the data obtained. This behavior was related to the presence of the CX3 group at the 7-position of the ring. In addition, an unusual equilibrium was observed for compound 6i. The result of 8i from 6i crystallization was attributed to the equilibrium 6i[Graphic 13]7i (in which 7i is the azide form).

Lastly, the evaluated series were very important to elucidate the factors that affect the equilibrium in distinct types of tetrazolo[1,5-a]pyrimidines in solution or solid state. These results support the substituent influence in both regioselectivity and tetrazole–azide equilibrium of tetrazolo[1,5-a]pyrimidines with great interest to biological or material sciences.


The reagents and solvents used were obtained from commercial suppliers without further purification. 1H and 13C NMR spectra were recorded on Bruker DPX 400 (1H at 400.13 MHz and 13C at 100.62 MHz) and Bruker DPX-200 (1H at 200.13 MHz and 13C at 50.32 MHz) spectrometers in CDCl3/TMS solutions at 298 K and in DMSO-d6/TMS solutions at 298 K. All spectra were acquired in a 5 mm tube at natural abundance. The chemical shifts (δ) are reported in ppm and J values are given in Hz. The melting points were measured using a Microquímica MQAPF 301 apparatus. The ionic liquid 1-butyl-3-methylimidazolium tetrafluoroborate [BMIM][BF4] was obtained commercially. The ionic liquid [HMIM][TsO] was prepared according to procedures described in the literature [50]. Additional information regarding the experimental data for the synthesized compounds is presented in Supporting Information File 1.

General procedure for obtaining single crystals

The single crystals of the compounds were obtained by slow evaporation of the solvents at 25 °C. Compounds 6a,b,f,h, and 8i were obtained from the solvent CHCl3. Suitable monocrystals for compounds 6d,e were obtained from solvent mixtures of ethyl acetate and EtOH (3:2).

General procedure for the synthesis of β-enaminones 1ai

β-Enaminones 1ai were prepared from the reaction of N,N-dimethylformamide dimethylacetal with methyl ketones in accordance with the methodology developed in our laboratory [31].

General procedure for the synthesis of tetrazolo[1,5-a]pyrimidines 3ag, 4ag, and 5h,i

A mixture of the 5-aminotetrazole (1.0 mmol) and the precursor β-enaminones 1 (1.0 mmol) in [HMIM][TsO] (1.0 mmol) and HCl (0.1 mmol) were placed in a round-bottomed flask and magnetically stirred for 5 min at 120 °C. After cooling, the resulting solid product was washed with water and collected by filtration using a funnel. The obtained products 3ag, 4a–g, and 5h,i were dried using a vacuum pump. Synthesis procedures and experimental data for 3a, 3g, 4a, 4g, and 5h can also be found in [21,32].

General procedure for the synthesis of (trichloromethyl)tetrazolo[1,5-a]pyrimidines 6h,i

In a manner closely related to a procedure from [37], a mixture of the 5-aminotetrazole (1.0 mmol) and the precursor β-enaminones 1 (1.0 mmol) in [BMIM][BF4] (1.0 mmol) and HCl (0.1 mmol) were placed in a round-bottomed flask and magnetically stirred for 6 h at 120 °C. After the reaction time, chloroform (30 mL) was added and the resulting mixture was washed with distilled water (3 × 10 mL), dried over sodium sulfate (Na2SO4), and the solvent was then removed under reduced pressure. The compounds 6h,i were obtained in pure form.

General procedure for the synthesis of tetrazolo[1,5-a]pyrimidines 8ac

A mixture of 5-aryl-7-trifluoromethyltetrazolo[1,5-a]pyrimidine 6ac (1.0 mmol), phenylacetylene (1 mmol), copper sulfate pentahydrate (10 mol %), and sodium ascorbate (20 mol %) in tert-butyl alcohol/water (1:1 mL) were placed in a round-bottomed flask and magnetically stirred at 60 °C for 24 h. After the reaction time was reached, chloroform (30 mL) was added and the resulting mixture was washed with distilled water (3 × 10 mL), dried over sodium sulfate (Na2SO4), and the solvent was then removed under reduced pressure. The compounds 8a–c were obtained in pure form.

Supporting Information

Supporting Information File 1: Additional material.
Format: PDF Size: 2.5 MB Download


The authors are grateful for the financial support from the National Council for Scientific and Technological Development (CNPq), Research Support Foundation of State of Rio Grande do Sul (FAPERGS) and the Coordination for Improvement of Higher Education Personnel (CAPES/PROEX). The fellowships from CNPq (M. A. P. M., C. R. B., and P.R.S.S.) and CAPES (A.R.M., A.B.P., T.O., G.C.Z.).


  1. Raju, C.; Madhaiyan, K.; Uma, R.; Sridhar, R.; Ramakrishna, S. RSC Adv. 2012, 2, 11657–11663. doi:10.1039/c2ra21330c
    Return to citation in text: [1] [2] [3]
  2. Aly, A. A. Phosphorus, Sulfur Silicon Relat. Elem. 2006, 181, 1285–1298. doi:10.1080/10426500500326792
    Return to citation in text: [1]
  3. Nagai, S.-I.; Ueda, T.; Sugiura, S.; Nagatsu, A.; Murakami, N.; Sakakibara, J.; Fujita, M.; Hotta, Y. J. Heterocycl. Chem. 1998, 35, 325–327. doi:10.1002/jhet.5570350211
    Return to citation in text: [1]
  4. Uehata, M.; Ono, T.; Satoh, H.; Yamagami, K.; Kawahara, T. Medicines Comprising Rho Kinase Inhibitor. U.S. Patent US 6,218,410 B1, April 17, 2001.
    Return to citation in text: [1]
  5. Aspnes, G. E.; Chiang, Y.-C. P. Tetrazole Compounds as Thyroid Receptor Ligands. U.S. Patent US 6,441,015 B2, Aug 27, 2002.
    Return to citation in text: [1]
  6. Fujii, A.; Tanaka, H.; Otsuki, M.; Kawaguchi, T.; Oshita, K. Antitumor effect potentiators. U.S. Patent US 6,930,115 B2, Aug 16, 2005.
    Return to citation in text: [1]
  7. Takayama, Y.; Yoshida, Y.; Uehata, M. Visual Function Disorder Improving Agents. U.S. Patent US 007109208 B2, Sept 19, 2006.
    Return to citation in text: [1]
  8. Hussein, A. M.; Ahmed, O. M. Bioorg. Med. Chem. 2010, 18, 2639–2644. doi:10.1016/j.bmc.2010.02.028
    Return to citation in text: [1]
  9. Hussein, A. M. J. Saudi Chem. Soc. 2010, 14, 61–68. doi:10.1016/j.jscs.2009.12.010
    Return to citation in text: [1]
  10. Takao Takaya, K.; Masayoshi Murata, O.; Kiyotaka Ito, I. Pyrimidine Compounds Having Activity as a Cardiotonic Anti-Hypertensive Cerebrovascular Vasodilator and Anti-Platelet Aggregation Agent. U.S. Patent US 4,725,600, Feb 16, 1988.
    Return to citation in text: [1]
  11. Utsunomiya, T.; Niki, T.; Kikuchi, T.; Watanabe, J.; Yamagishi, K.; Nishioka, M.; Suzuki, H.; Furusato, T.; Miyake, T. Tetrazole Compounds and Pest Control Agent. WO Patent WO 1999006380 A1, Feb 11, 1999.
    Return to citation in text: [1]
  12. Abelman, M.; Jiang, R.; Zablocki, J. Substituted heterocyclic compounds. U.S. Patent US 2009/0181986 A1, July 16, 2009.
    Return to citation in text: [1]
  13. Dougherty, A. M.; Guo, H.; Westby, G.; Liu, Y.; Simsek, E.; Guo, J.-T.; Mehta, A.; Norton, P.; Gu, B.; Block, T.; Cuconati, A. Antimicrob. Agents Chemother. 2007, 51, 4427–4437. doi:10.1128/AAC.00541-07
    Return to citation in text: [1]
  14. Raju, C.; Kalaipriya, M.; Uma, R.; Sridhar, R.; Ramakrishna, S. Curr. Chem. Lett. 2012, 1, 27–34. doi:10.5267/j.ccl.2011.12.004
    Return to citation in text: [1]
  15. Zeng, L.-Y.; Cai, C. J. Comb. Chem. 2010, 12, 35–40. doi:10.1021/cc9000983
    Return to citation in text: [1]
  16. Yao, C.; Lei, S.; Wang, C.; Yu, C.; Tu, S. J. Heterocycl. Chem. 2008, 45, 1609–1613. doi:10.1002/jhet.5570450609
    Return to citation in text: [1]
  17. Ghorbani-Vaghei, R.; Toghraei-Semiromi, Z.; Amiri, M.; Karimi-Nami, R. Mol. Diversity 2013, 17, 307–318. doi:10.1007/s11030-013-9435-0
    Return to citation in text: [1]
  18. Desenko, S. M.; Gladkov, E. S.; Komykhov, S. A.; Shishkin, O. V.; Orlov, V. D. Chem. Heterocycl. Compd. 2001, 37, 747–754. doi:10.1023/A:1011925631511
    Return to citation in text: [1]
  19. Gein, V. L.; Gein, L. F.; Tsyplyakova, E. P.; Panova, O. S. Russ. J. Org. Chem. 2007, 43, 1382–1386. doi:10.1134/S1070428007090205
    Return to citation in text: [1]
  20. Kanyalkar, M.; Coutinho, E. C. Tetrahedron 2000, 56, 8775–8777. doi:10.1016/S0040-4020(00)00819-X
    Return to citation in text: [1] [2] [3]
  21. Krivopalov, V. P.; Mamatyuk, V. I.; Nikolaenkova, E. B. Russ. Chem. Bull. 1995, 44, 1435–1443. doi:10.1007/BF00714425
    Return to citation in text: [1] [2] [3] [4] [5] [6] [7] [8]
  22. Bajwa, J. S.; Sykes, P. J. J. Chem. Soc., Perkin Trans. 1 1979, 3085–3094. doi:10.1039/p19790003085
    Return to citation in text: [1] [2] [3]
  23. Cubero, E.; Orozco, M.; Luque, F. J. J. Am. Chem. Soc. 1998, 120, 4723–4731. doi:10.1021/ja9726724
    Return to citation in text: [1] [2]
  24. Temple, C., Jr.; McKee, R. L.; Montgomery, J. A. J. Org. Chem. 1962, 27, 1671–1673. doi:10.1021/jo01052a045
    Return to citation in text: [1] [2] [3]
  25. Boyer, J.; Hyde, H. J. Org. Chem. 1960, 25, 458–459. doi:10.1021/jo01073a608
    Return to citation in text: [1] [2]
  26. Temple, C., Jr.; Thorpe, M. C.; Coburn, W. C., Jr.; Montgomery, J. A. J. Org. Chem. 1966, 31, 935–938. doi:10.1021/jo01341a071
    Return to citation in text: [1] [2] [3]
  27. Temple, C., Jr.; Montgomery, J. A. J. Org. Chem. 1965, 30, 826–829. doi:10.1021/jo01014a041
    Return to citation in text: [1] [2] [3]
  28. Pochinok, V. Y.; Avramenko, L. F.; Grigorenko, P. S.; Skopenko, V. N. Russ. Chem. Rev. 1975, 44, 481–492. doi:10.1070/RC1975v044n06ABEH002355
    Return to citation in text: [1] [2]
  29. Martins, M. A. P.; Scapin, E.; Frizzo, C. P.; Rosa, F. A.; Bonacorso, H. G.; Zanatta, N. J. Braz. Chem. Soc. 2009, 20, 205–213. doi:10.1590/S0103-50532009000200003
    Return to citation in text: [1]
  30. Frizzo, C. P.; Scapin, E.; Marzari, M. R. B.; München, T. S.; Zanatta, N.; Bonacorso, H. G.; Buriol, L.; Martins, M. A. P. Ultrason. Sonochem. 2014, 21, 958–962. doi:10.1016/j.ultsonch.2013.12.007
    Return to citation in text: [1]
  31. Martins, M. A. P.; Frizzo, C. P.; Moreira, D. N.; Rosa, F. A.; Marzari, M. R. B.; Zanatta, N.; Bonacorso, H. G. Catal. Commun. 2008, 9, 1375–1378. doi:10.1016/j.catcom.2007.11.037
    Return to citation in text: [1] [2]
  32. Krasovsky, A. L.; Moiseev, A. M.; Nenajdenko, V. G.; Balenkova, E. S. Synthesis 2002, 901–905. doi:10.1055/s-2002-28512
    Return to citation in text: [1] [2] [3] [4] [5] [6]
  33. Shao, Y.; Zhu, K.; Qin, Z.; Li, E.; Li, Y. J. Org. Chem. 2013, 78, 5731–5736. doi:10.1021/jo4005553
    Return to citation in text: [1]
  34. Xu, H.; Zhou, B.; Zhou, P.; Zhou, J.; Shen, Y.; Yu, F.-C.; Lu, L.-L. Chem. Commun. 2016, 52, 9471–9472. doi:10.1039/C6CC90308H
    Return to citation in text: [1]
  35. Gaussian 09, Revision A.02; Gaussian, Inc.: Wallingford CT, 2016.
    Return to citation in text: [1] [2] [3]
  36. Sirakanyan, S. N.; Spinelli, D.; Geronikaki, A.; Kartsev, V. G.; Panosyan, H. A.; Ayvazyan, A. G.; Tamazyan, R. A.; Frenna, V.; Hovakimyan, A. A. Tetrahedron 2016, 72, 1919–1927. doi:10.1016/j.tet.2016.02.048
    Return to citation in text: [1] [2]
  37. Scapin, E.; Frizzo, C. P.; Rodrigues, L. V.; Zimmer, G. C.; Vaucher, R. A.; Sagrillo, M. R.; Giongo, J. L.; Afonso, C. A. M.; Rijo, P.; Zanatta, N.; Bonacorso, H. G.; Martins, M. A. P. Med. Chem. Res. 2017, 26, 640–649. doi:10.1007/s00044-017-1783-3
    Return to citation in text: [1] [2] [3] [4] [5]
  38. Shestakova, T. S.; Shenkarev, Z. O.; Deev, S. L.; Chupakhin, O. N.; Khalymbadzha, I. A.; Rusinov, V. L.; Arseniev, A. S. J. Org. Chem. 2013, 78, 6975–6982. doi:10.1021/jo4008207
    Return to citation in text: [1]
  39. Cmoch, P.; Stefaniak, L.; Webb, G. A. Magn. Reson. Chem. 1997, 35, 237–242. doi:10.1002/(SICI)1097-458X(199704)35:4<237::AID-OMR63>3.0.CO;2-L
    Return to citation in text: [1]
  40. Cmoch, P. Magn. Reson. Chem. 2002, 40, 507–516. doi:10.1002/mrc.1055
    Return to citation in text: [1]
  41. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596–2599. doi:10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4
    Return to citation in text: [1] [2]
  42. Hein, J. E.; Fokin, V. V. Chem. Soc. Rev. 2010, 39, 1302–1315. doi:10.1039/b904091a
    Return to citation in text: [1]
  43. Tornøe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057–3064. doi:10.1021/jo011148j
    Return to citation in text: [1]
  44. Cornec, A.-S.; Baudequin, C.; Fiol-Petit, C.; Plé, N.; Dupas, G.; Ramondenc, Y. Eur. J. Org. Chem. 2013, 1908–1915. doi:10.1002/ejoc.201201033
    Return to citation in text: [1] [2]
  45. Farrugia, L. J. J. Appl. Crystallogr. 1997, 30, 565. doi:10.1107/S0021889897003117
    Return to citation in text: [1] [2]
  46. Sirakanyan, S. N.; Geronikaki, A.; Spinelli, D.; Hovakimyan, A. A.; Noravyan, A. S. Tetrahedron 2013, 69, 10637–10643. doi:10.1016/j.tet.2013.10.015
    Return to citation in text: [1]
  47. Bajwa, J. S.; Sykes, P. J. J. Chem. Soc., Perkin Trans. 1 1980, 1019–1024. doi:10.1039/p19800001019
    Return to citation in text: [1]
  48. Abu-Eittah, R. H.; El-Taher, S.; Hassan, W. M. I.; Noamaan, M. A. Comput. Theor. Chem. 2014, 1033, 52–59. doi:10.1016/j.comptc.2014.01.024
    Return to citation in text: [1]
  49. Abu-Eittah, R. H.; El-Kelany, K. E. Spectrochim. Acta, Part A 2012, 99, 316–328. doi:10.1016/j.saa.2012.08.012
    Return to citation in text: [1]
  50. Zhao, G.; Jiang, T.; Gao, H.; Han, B.; Huang, J.; Sun, D. Green Chem. 2004, 6, 75–77. doi:10.1039/b309700p
    Return to citation in text: [1]
Other Beilstein-Institut Open Science Activities